The impact of immune checkpoint inhibitors on cost and quality of life in the initial treatment of patients with advanced or metastatic NSCLC

Procailo, Kelly Marie

doi:10.37765/ajmc.2021.88770

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in targeted immuno-oncology has revolutionised and reformed the treatment pattern. 2 Drugs targeting and binding to PD-1 and PD-L1 (such as nivolumab plus ipilimumab, pembrolizumab, atezolizumab, and cemiplimab) as first-line treatment for advanced or metastatic NSCLC with driver gene negativity have been approved by the United States Food and Drug Administration. The lack of predictive indicators is an important reason for unsatisfactory immunotherapy outcomes, unlike those in targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor

Fang

Luo

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Low baseline prognostic nutritional index (PNI) scores are associated with poor survival for various malignancies; however, they vary based on the cohort and time resulting in inaccurate results. We determined the predictive value of the PNI score variations in addition to the baseline PNI scores for patients with advanced non-small cell lung cancer (NSCLC) who received programmed cell death protein 1 (PD-1) inhibitor. Methods: We retrospectively analysed 115 patients with advanced NSCLC who received PD-1 inhibitor. The median follow-up period was 28 months. Patients were clustered into four groups based on the combined PNI scores (combination of baseline and variation of PNI scores): ΔPNI-L-L, ΔPNI-L-H, ΔPNI-H-L, and ΔPNI-H-H subgroups. For instance, if PNI scores of patients with high baseline PNI score increased from baseline to 6 weeks after treatment, they were included in the ΔPNI-H-H subgroup. Cox regression models were used to identify the factors associated with survival. Results: The baseline PNI score was only related to the overall survival (OS) ( P = .026), and not to the overall response rate (ORR) ( P = .299) and progression-free survival (PFS) ( P = .207). The ORR was associated with the combined PNI scores ( P = .017). A multivariable Cox regression analysis confirmed that the combined PNI scores were independent factors for PFS (ΔPNI-L-H, 12 months, hazard ratio [HR] = 0.449, P = .009; ΔPNI-H-L, 14 months, HR = 0.500, P = .019; and ΔPNI-H-H, 17 months, HR = 0.390, P = .012; vs ΔPNI-L-L, 8 months) and OS (ΔPNI-L-H, 27 months, HR = 0.403, P = .019; ΔPNI-H-L, 28 months, HR = 0.369, P = .010; and ΔPNI-H-H, not reached, HR = 0.087, P = .002; vs ΔPNI-L-L, 15 months). Conclusions: Patients with high baseline PNI and increased PNI score had the better survival outcome. On dynamic monitoring and comprehensive assessment, the combined PNI scores significantly enhanced the survival predictive ability of patients with NSCLC treated with PD-1 inhibitor.

show abstract

Section: Introductionmentioning

confidence: 99%